Mycobacterium bolletii respiratory infections

Emerging Infectious Diseases

Volumn 15, Issue 2, 2009, Pages 302-305

  Adékambi, Toïdi ^a,b   Drancourt, Michel ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; CEFOTAXIME; CEFOXITIN; CEFTRIAXONE; CIPROFLOXACIN; CLARITHROMYCIN; CORTICOSTEROID; COTRIMOXAZOLE; DOXYCYCLINE; ERYTHROMYCIN; ETHAMBUTOL; IMIPENEM; ISONIAZID; MACROLIDE; METRONIDAZOLE; MINOCYCLINE; OFLOXACIN; PENICILLIN G; RIBOSOME DNA; RIBOSOME PROTEIN; RIBOSOME PROTEIN L22; RIBOSOME PROTEIN L4; RIFAMPICIN; SPARFLOXACIN; TEICOPLANIN; TOBRAMYCIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ACID FAST BACTERIUM; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATION; BLEEDING; BRONCHITIS; BRONCHOSCOPY; CLINICAL ARTICLE; COUGHING; FEMALE; GENE MUTATION; HEMOPTYSIS; HUMAN; INFLAMMATION; INTENSIVE CARE UNIT; KLEBSIELLA PNEUMONIAE; LUNG EMPHYSEMA; LUNG TUBERCULOSIS; MALE; MICROSCOPY; MULTIDRUG RESISTANCE; MYCOBACTERIOSIS; MYCOBACTERIUM; MYCOBACTERIUM ABSCESSUS; MYCOBACTERIUM BOLLETII; MYCOBACTERIUM CHELONEI; NUCLEOTIDE SEQUENCE; POLYMORPHONUCLEAR CELL; RESPIRATORY FAILURE; RESPIRATORY TRACT INFECTION; SPUTUM CULTURE; THORAX RADIOGRAPHY; TRACHEOBRONCHIAL TOILET; TREATMENT DURATION;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; ANTITUBERCULAR AGENTS; DNA, BACTERIAL; DNA, RIBOSOMAL; FATAL OUTCOME; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MYCOBACTERIUM; MYCOBACTERIUM INFECTIONS; RESPIRATORY TRACT INFECTIONS; RNA, RIBOSOMAL, 23S; SEQUENCE ANALYSIS, DNA; SPUTUM; TUBERCULOSIS, PULMONARY;

EID: 63849177561     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1502.080837     Document Type: Article

References (15)

1. Brown-Elliott BA, Wallace RJ Jr. Clinical and taxonomic status of pathogenic nonpigmented or late-pigmenting rapidly growing mycobacteria. Clin Microbiol Rev. 2002;15:716-46. DOI: 10.1128/ CMR.15.4.716-746.2002
2. Griffith DE. Emergence of nontuberculous mycobacteria as pathogens in cystic fibrosis. Am J Respir Crit Care Med. 2003;167:810-2. DOI: 10.1164/rccm.2301001
3. Sanguinetti M, Ardito F, Fiscarelli E, La Sorda M, D'Argenio P, Ric- ciotti G, et al. Fatal pulmonary infection due to multidrug-resistant Mycobacterium abscessus in a patient with cystic fibrosis. J Clin Microbiol. 2001;39:816-9. DOI: 10.1128/JCM.39.2.816-819.2001
4. Adekambi T, Berger P, Raoult D, Drancourt M. rpoB gene sequence- based characterization of emerging non-tuberculous mycobacteria with descriptions of Mycobacterium bolletii sp. nov., Mycobacterium phocaicum sp. nov. and Mycobacterium aubagnense sp. nov. Int J Syst Evol Microbiol. 2006;56:133-43. DOI: 10.1099/ijs.0.63969-0
5. Roux AL, Catherinot E, Rippoll F, Soismier N, Guterriez C, Vincent V, et al. Mycobacteries non-tuberculeuses et mucoviscidoses: enquête française de prevalence. Abstract 9ème Colloque des Jeunes Chercheurs en Mucoviscidose, Paris, 2008.
6. Adékambi T, Colson P, Drancourt M. rpoB-based identification of nonpigmented and late-pigmenting rapidly growing mycobacteria. J Clin Microbiol. 2003;41:5699-708. DOI: 10.1128/JCM.41.12.5699-5708.2003
7. National Committee for Clinical Laboratory Standards. Susceptibility testing of Mycobacteria, Nocardia, and other aerobic actino- mycetes. Approved standard M24-A. Wayne (PA): The Committee; 2003..
8. Meier A, Kirschner P, Springer B, Steingrube VA, Brown BA, Wallace RJ Jr, et al. Identification of mutations in 23S rRNA gene of clarithromycin-resistant Mycobacterium intracellulare. Antimicrob Agents Chemother. 1994;38:381-4.
9. Simmon KE, Pounder JI, Greene JN, Walsh F, Anderson CM, Cohen S, et al. Identification of an emerging pathogen, Mycobacterium massiliense, by rpoB sequencing of clinical isolates collected in the United States. J Clin Microbiol. 2007;45:1978-80. DOI: 10.1128/JCM.00563-07
10. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An official ATS/IDSA statement: diagnosis, treatment, and revention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175:367-416. DOI: 10.1164/rccm.200604-571ST
11. Viana-Niero C, Lima KV, Lopes ML, Rabello MC, Marsola LR, Brilhante VC, et al. Molecular characterization of Mycobacte- rium massiliense and Mycobacterium bolletii in isolates collected from outbreaks of infections after laparoscopic surgeries and cosmetic procedures. J Clin Microbiol. 2008;46:850-5. DOI: 10.1128/JCM.02052-07
12. Wallace RJ Jr, Meier A, Brown BA, Zhang Y, Sander P, Onyi GO, et al. Genetic basis for clarithromycin resistance among isolates of Mycobacterium chelonae and Mycobacterium abscessus. Antimi- crob Agents Chemother. 1996;40:1676-81.
13. Canu A, Malbruny B, Coquemont M, Davies TA, Appelbaum PC, Leclercq R. Diversity of ribosomal mutations conferring resistance to macrolides, clindamycin, streptogramin, and telithromy- cin in Streptococcus pneumoniae. Antimicrob Agents Chemother. 2002;46:125-31. DOI: 10.1128/AAC.46.1.125-131.2002
14. Nash KA, Andini N, Zhang Y, Brown-Elliott BA, Wallace RJ Jr. Intrinsic macrolide resistance in rapidly growing mycobacteria. Antimicrob Agents Chemother. 2006;50:3476-8. DOI: 10.1128/AAC.00402-06
15. Yang SC, Hsueh PR, Lai HC, Teng LJ, Huang LM, Chen JM, et al. High prevalence of antimicrobial resistance in rapidly growing mycobacteria in Taiwan. Antimicrob Agents Chemother. 2003;47:1958- 62. DOI: 10.1128/AAC.47.6. 1958-1962.2003